(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 182% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Lenz Therapeutics's revenue in 2025 is $5,000,000.On average, 5 Wall Street analysts forecast LENZ's revenue for 2025 to be $406,981,788, with the lowest LENZ revenue forecast at $324,838,151, and the highest LENZ revenue forecast at $446,656,023. On average, 5 Wall Street analysts forecast LENZ's revenue for 2026 to be $1,343,618,898, with the lowest LENZ revenue forecast at $1,175,110,355, and the highest LENZ revenue forecast at $1,517,375,507.
In 2027, LENZ is forecast to generate $3,427,699,931 in revenue, with the lowest revenue forecast at $2,994,820,080 and the highest revenue forecast at $3,967,423,554.